Kevin B Kim

7PUBLICATIONS
35CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Feb 25, 2026
Retrospective Study of Trametinib in Patients With Advanced NF1-Mutant Melanoma.

Lin Wang, Mohammed Kashani-Sabet, Prasad Dighe

|May 15, 2025
Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations.

Kevin B Kim, Pierre-Yves Desprez, David de Semir

|Jun 27, 2024
Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches.

Kevin B Kim

|Jun 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Omid Hamid, Karl D Lewis, Amy Weise

|Jul 19, 2018
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.

Thein Swe, Kevin B Kim

Pageof 2

Frequent Collaborators

2 joint publications

Meredith McKean

2 joint publications

Janice Mehnert

2 joint publications

Mohammed Kashani-Sabet

1 joint publications

Omid Hamid